You have a decent health plan through work and a doctor you like. What you do not have is the right vocabulary. You know the antidepressants have not done enough. You have maybe read a headline about esketamine. You are not sure how to bring it up without sounding like you are ordering off a menu.
This script is built for exactly that situation. It covers three conversations: the one with your doctor, the one with your insurer, and the one with a treatment center.
Why it helps to have words ready
Most people have never heard of this treatment. When our commissioned survey asked 443 Midwest adults about Spravato, 73 percent found the name entirely unfamiliar, and only 6 percent could explain it. If your doctor has not mentioned it, that may simply be because patients so rarely ask. A brief guide to Spravato can help you prepare.
Your doctor's opinion also carries unusual weight. The most persuasive push toward a new depression treatment, for 74 percent of respondents, was their own doctor's recommendation. Of the 173 respondents with commercial coverage, 81 percent said the same. So the goal is not to talk your doctor into anything. It is to get their honest opinion on the table.
The survey numbers here are final and validated. Beyond that single commercial-coverage figure, the insurance steps below are practical guidance, not survey findings.
Conversation one: your doctor
Open with the problem, not the product.
"I want to spend today on my depression. I have tried two antidepressants now, and I am still not doing well."
Give the history. Bring a written list and hand it over.
"Here is what I have taken, the doses, and roughly how long. I stopped this one because of side effects, and this one just never helped much."
Ask about the category.
"Would this count as treatment-resistant depression?"
This matters because commercial insurers often use that definition when deciding whether to cover next-step treatments.
Ask about options, including esketamine.
"What are my options at this point? I have heard of a nasal spray called esketamine, or Spravato. Is that something you would consider for me? And if not, why not?"
If your doctor thinks it is a poor fit, ask for their alternative. Several next steps exist, and your doctor knows your history.
Ask about the paperwork.
"If we go that route, what will my insurance need? Can your office start a prior authorization, or does the treatment center do that?"
Ask about where.
"Where do you usually send people for this? Somewhere reasonably close would really help, since I understand I would need a ride home each time."
Proximity mattered to 43 percent of our respondents, second only to coverage.
Conversation two: your insurer
Dial the phone number printed on your insurance card. Have your member ID ready.
"I am calling to ask about coverage for esketamine nasal spray, brand name Spravato, for treatment-resistant depression. Is it covered on my plan?"
"Does it need prior authorization? What criteria do you use?"
"Is this billed to my medical coverage or my prescription coverage? How does that change what I pay?"
"Can you tell me which certified treatment centers near my ZIP code are in network?"
"What will my cost be per visit, including the observation time, and how much of my deductible have I met this year?"
Before hanging up:
"Can I have a reference number for this call, and your name?"
Coverage is what most people care about. Eighty-five percent of our respondents counted insurance among their two chief provider concerns, and just over half would tolerate added steps if it kept a treatment covered. A single well-documented call can remove a lot of those steps.
Conversation three: the treatment center
"My doctor is referring me for esketamine. I have a commercial plan through my employer. Are you in network with it for this treatment?"
"Do you handle the prior authorization? What do you need from my doctor?"
"What does the first month look like? How many visits, and how long is each one?"
"Do you have appointment times that would work around a full-time job?"
"Is there a cost-support program I should apply for?"
The manufacturer offers a patient support program with cost assistance that some commercially insured patients qualify for. Government plans are usually excluded.
If you hear about at-home ketamine instead
Some clinics and online services offer ketamine rather than esketamine. You can ask directly:
"Is this the approved esketamine, given at a certified site, or ketamine prescribed off-label? Will my insurance cover it?"
Off-label ketamine, particularly at home, involves much less supervision and is often cash-pay. It is a separate decision, and worth discussing with your doctor before committing.
If the insurer says no
"Can you tell me the specific reason for the denial, and send it to me in writing?"
Then take that letter to your doctor:
"The insurer denied it for this reason. Can we send more documentation, or request a peer-to-peer review? And what is the appeal process?"
Commercial plans must offer an appeal process, and many cases also qualify for an independent external review.
Keep a simple log
Across all three conversations, write down who you spoke with, the date, and what they said. A single page with those notes turns a confusing week of phone calls into a record you can hand to your doctor if something goes wrong, and it spares you from repeating your story from the start each time.
If you freeze
Bring this page. Hand it to your doctor. Or send a portal message afterward. Depression makes self-advocacy hard. Written words carry the message when your voice will not.
If you are thinking about suicide, say that first, before any of this. And if the next appointment feels too far away, call or text 988 right now and a trained listener from the Suicide and Crisis Lifeline will take it; veterans can press 1. Your insurance plan does not matter there, and neither does the hour.
Methodology
Survey results come from the Pollfish consumer panel, where 443 people, ages 18 to 64, from Nebraska, Oklahoma, Missouri, Iowa, Minnesota, Illinois, Ohio, Indiana, Kansas, and Wisconsin answered our questions. Fieldwork closed June 23, 2026. Apart from the commercial-coverage figure, only whole-sample percentages are cited. Results reflect the panel's final validation. The publisher commissioned this survey and paid for it outright. These scripts are suggestions, not medical or insurance advice.